{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T07:38:54Z","timestamp":1791185934107,"version":"4.1.0"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1007\/s40265-014-0217-5","type":"journal-article","created":{"date-parts":[[2014,5,6]],"date-time":"2014-05-06T13:58:16Z","timestamp":1399384696000},"page":"729-736","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":87,"title":["Serotonergic Therapies for Cognitive Symptoms in Alzheimer\u2019s Disease: Rationale and Current Status"],"prefix":"10.1007","volume":"74","author":[{"given":"Maria J.","family":"Ramirez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell K. P.","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa M.","family":"Tordera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul T.","family":"Francis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,5,7]]},"reference":[{"key":"217_CR1","unstructured":"Alzheimer\u2019s Association. http:\/\/www.alz.org . Accessed 17 Apr 2014."},{"key":"217_CR2","unstructured":"Alzheimer\u00b4s Association. Alzheimer\u2019s Association TrialMatch\u00ae. http:\/\/www.alz.org\/research\/clinical_trials\/find_clinical_trials_trialmatch.asp . Accessed 17 Apr 2014."},{"issue":"9","key":"217_CR3","doi-asserted-by":"crossref","first-page":"765","DOI":"10.2165\/11590190-000000000-00000","volume":"25","author":"WJ Geldenhuys","year":"2011","unstructured":"Geldenhuys WJ, Van der Schyf CJ. Role of serotonin in Alzheimer\u2019s disease: a new therapeutic target? CNS Drugs. 2011;25(9):765\u201381.","journal-title":"CNS Drugs"},{"key":"217_CR4","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.coph.2011.01.004","volume":"11","author":"X Codony","year":"2011","unstructured":"Codony X, Vela JM, Ram\u00edrez MJ. 5-HT(6) receptor and cognition. Curr Opin Pharmacol. 2011;11:94\u2013100.","journal-title":"Curr Opin Pharmacol"},{"issue":"2","key":"217_CR5","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/alzrt169","volume":"5","author":"MJ Ram\u00edrez","year":"2013","unstructured":"Ram\u00edrez MJ. 5-HT6 receptors and Alzheimer\u2019s disease. Alzheimers Res Ther. 2013;5(2):15.","journal-title":"Alzheimers Res Ther"},{"issue":"48","key":"217_CR6","doi-asserted-by":"crossref","first-page":"44881","DOI":"10.1074\/jbc.M109008200","volume":"276","author":"SJ Robert","year":"2001","unstructured":"Robert SJ, Zugaza JL, Fischmeister R, Gardier AM, Lezoualc\u2019h F. The human serotonin 5-HT4 receptor regulates secretion of non-amyloidogenic precursor protein. J Biol Chem. 2001;276(48):44881\u20138.","journal-title":"J Biol Chem"},{"key":"217_CR7","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1146\/annurev.neuro.051508.135607","volume":"32","author":"P Dayan","year":"2009","unstructured":"Dayan P, Huys QJ. Serotonin in affective control. Annu Rev Neurosci. 2009;32:95\u2013126.","journal-title":"Annu Rev Neurosci"},{"issue":"4","key":"217_CR8","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2174\/187152709788921654","volume":"8","author":"E Murillo-Rodriguez","year":"2009","unstructured":"Murillo-Rodriguez E, Arias-Carrion O, Sanguino-Rodriguez K, Gonzalez-Arias M, Haro R. Mechanisms of sleep-wake cycle modulation. CNS Neurol Disord Drug Targets. 2009;8(4):245\u201353.","journal-title":"CNS Neurol Disord Drug Targets"},{"issue":"5","key":"217_CR9","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1152\/japplphysiol.01270.2009","volume":"108","author":"MR Hodges","year":"2010","unstructured":"Hodges MR, Richerson GB. The role of medullary serotonin (5-HT) neurons in respiratory control: contributions to eupneic ventilation, CO2 chemoreception, and thermoregulation. J Appl Physiol. 2010;108(5):1425\u201332.","journal-title":"J Appl Physiol"},{"issue":"6","key":"217_CR10","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1179\/147683010X12611460764723","volume":"13","author":"CP Magalh\u00e3es","year":"2010","unstructured":"Magalh\u00e3es CP, de Freitas MF, Nogueira MI, Campina RC, Takase LF, de Souza SL, et al. Modulatory role of serotonin on feeding behavior. Nutr Neurosci. 2010;13(6):246\u201355.","journal-title":"Nutr Neurosci"},{"issue":"4","key":"217_CR11","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jchemneu.2011.04.005","volume":"41","author":"M Parent","year":"2011","unstructured":"Parent M, Wallman MJ, Gagnon D, Parent A. Serotonin innervation of basal ganglia in monkeys and humans. J Chem Neuroanat. 2011;41(4):256\u201365.","journal-title":"J Chem Neuroanat"},{"issue":"1","key":"217_CR12","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1152\/physrev.1992.72.1.165","volume":"72","author":"BL Jacobs","year":"1992","unstructured":"Jacobs BL, Azmitia EC. Structure and function of the brain serotonin system. Physiol Rev. 1992;72(1):165\u2013229.","journal-title":"Physiol Rev"},{"issue":"5\u20136","key":"217_CR13","first-page":"543","volume":"23","author":"A Meneses","year":"2012","unstructured":"Meneses A, Liy-Salmeron G. Serotonin and emotion, learning and memory. Rev Neurosci. 2012;23(5\u20136):543\u201353.","journal-title":"Rev Neurosci"},{"issue":"8","key":"217_CR14","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1111\/j.1460-9568.2011.07621.x","volume":"33","author":"MJ Wallman","year":"2011","unstructured":"Wallman MJ, Gagnon D, Parent M. Serotonin innervation of human basal ganglia. Eur J Neurosci. 2011;33(8):1519\u201332.","journal-title":"Eur J Neurosci"},{"issue":"8","key":"217_CR15","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S0028-3908(99)00010-6","volume":"38","author":"NM Barnes","year":"1999","unstructured":"Barnes NM, Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology. 1999;38(8):1083\u2013152.","journal-title":"Neuropharmacology"},{"issue":"4","key":"217_CR16","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0091-3057(01)00746-8","volume":"71","author":"D Hoyer","year":"2002","unstructured":"Hoyer D, Hannon JP, Martin GR. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav. 2002;71(4):533\u201354.","journal-title":"Pharmacol Biochem Behav"},{"issue":"9","key":"217_CR17","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.tips.2008.06.007","volume":"29","author":"MJ Millan","year":"2008","unstructured":"Millan MJ, Marin P, Bockaert J, Mannoury la Cour C. Signaling at G-protein-coupled serotonin receptors: recent advances and future research directions. Trends Pharmacol Sci. 2008;29(9):454\u201364.","journal-title":"Trends Pharmacol Sci"},{"issue":"3\u20134","key":"217_CR18","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/0028-3908(94)90067-1","volume":"33","author":"AT Bruinvels","year":"1994","unstructured":"Bruinvels AT, Landwehrmeyer B, Gustafson EL, Durkin MM, Mengod G, Branchek TA, et al. Localization of 5-HT1B, 5-HT1D alpha, 5-HT1E and 5-HT1F receptor messenger RNA in rodent and primate brain. Neuropharmacology. 1994;33(3\u20134):367\u201386.","journal-title":"Neuropharmacology"},{"issue":"3","key":"217_CR19","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3109\/07853890008998828","volume":"32","author":"MC Buhot","year":"2000","unstructured":"Buhot MC, Martin S, Segu L. Role of serotonin in memory impairment. Ann Med. 2000;32(3):210\u201321.","journal-title":"Ann Med"},{"issue":"8","key":"217_CR20","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1038\/sj.npp.1301294","volume":"32","author":"P Bonsi","year":"2007","unstructured":"Bonsi P, Cuomo D, Ding J, Sciamanna G, Ulrich S, Tscherter A, et al. Endogenous serotonin excites striatal cholinergic interneurons via the activation of 5-HT 2C, 5-HT6, and 5-HT7 serotonin receptors: implications for extrapyramidal side effects of serotonin reuptake inhibitors. Neuropsychopharmacology. 2007;32(8):1840\u201354.","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"217_CR21","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.bbr.2008.06.011","volume":"195","author":"J Borg","year":"2008","unstructured":"Borg J. Molecular imaging of the 5-HT1A receptor in relation to human cognition. Behav Brain Res. 2008;195(1):103\u201311.","journal-title":"Behav Brain Res"},{"issue":"5","key":"217_CR22","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S0893-133X(01)00265-2","volume":"25","author":"LA Dawson","year":"2001","unstructured":"Dawson LA, Nguyen HQ, Li P. The 5-HT6 receptor antagonist SB-271046 selectively enhances excitatory neurotransmission in the rat frontal cortex and hippocampus. Neuropsychopharmacology. 2001;25(5):662\u20138.","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"217_CR23","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1101\/lm.60803","volume":"10","author":"JA Harvey","year":"2003","unstructured":"Harvey JA. Role of the serotonin 5-HT2A receptor in learning. Learn Mem. 2003;10(5):355\u201362.","journal-title":"Learn Mem"},{"issue":"3 Pt 2","key":"217_CR24","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1523\/JNEUROSCI.15-03-02445.1995","volume":"15","author":"U Staubli","year":"1995","unstructured":"Staubli U, Xu FB. Effects of 5-HT3 receptor antagonism on hippocampal theta rhythm, memory, and LTP induction in the freely moving rat. J Neurosci. 1995;15(3 Pt 2):2445\u201352.","journal-title":"J Neurosci"},{"issue":"4","key":"217_CR25","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.neuropharm.2007.06.016","volume":"53","author":"EG Mohler","year":"2007","unstructured":"Mohler EG, Shacham S, Noiman S, Lezoualc\u2019h F, Robert S, Gastineau M, et al. VRX-03011, a novel 5-HT4 agonist, enhances memory and hippocampal acetylcholine efflux. Neuropharmacology. 2007;53(4):563\u201373.","journal-title":"Neuropharmacology"},{"issue":"5\u20136","key":"217_CR26","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1023\/A:1021800822997","volume":"22","author":"A Meneses","year":"2002","unstructured":"Meneses A. Involvement of 5-HT2A\/2B\/2C receptors on memory formation: simple agonism, antagonism, or inverse agonism? Cell Mol Neurobiol. 2002;22(5\u20136):675\u201388.","journal-title":"Cell Mol Neurobiol"},{"issue":"9","key":"217_CR27","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.tips.2004.07.002","volume":"25","author":"PB Hedlund","year":"2004","unstructured":"Hedlund PB, Sutcliffe JG. Functional, molecular and pharmacological advances in 5-HT7 receptor research. Trends Pharmacol Sci. 2004;25(9):481\u20136.","journal-title":"Trends Pharmacol Sci"},{"key":"217_CR28","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/j.1471-4159.1983.tb11838.x","volume":"41","author":"DM Bowen","year":"1983","unstructured":"Bowen DM, Allen SJ, Benton JS, Goodhardt MJ, Haan EA, Palmer AM, Sims NR, Smith CC, Spillane JA, Esiri MM, Neary D, Snowdon JS, Wilcock GK, Davison AN. Biochemical assessment of serotonergic and cholinergic dysfunction and cerebral atrophy in Alzheimer\u2019s disease. J Neurochem. 1983;41:266\u201372.","journal-title":"J Neurochem"},{"key":"217_CR29","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1046\/j.1471-4159.1996.66041592.x","volume":"66","author":"CPLH Chen","year":"1996","unstructured":"Chen CPLH, Alder JT, Bowen DM, Esiri MM, McDonald B, Hope T, Jobst KA, Francis PT. Presynaptic serotonergic markers in community-acquired cases of Alzheimer\u2019s disease: correlation with depression and neuroleptic medication. J Neurochem. 1996;66:1592\u20138.","journal-title":"J Neurochem"},{"key":"217_CR30","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1046\/j.1365-2990.2000.00254.x","volume":"26","author":"CPLH Chen","year":"2000","unstructured":"Chen CPLH, Eastwood SL, Hope T, McDonald B, Francis PT, Esiri MM. Immunocytochemical study of the dorsal and median raphe nuclei in patients with Alzheimer\u2019s disease prospectively assessed for behavioural changes. Neuropathol Appl Neurobiol. 2000;26:347\u201355.","journal-title":"Neuropathol Appl Neurobiol"},{"key":"217_CR31","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1471-4159.1987.tb13120.x","volume":"48","author":"AM Palmer","year":"1987","unstructured":"Palmer AM, Francis PT, Benton JS, Sims NR, Mann DM, Neary D, Snowden JS, Bowen DM. Presynaptic serotonergic dysfunction in patients with Alzheimer\u2019s disease. J Neurochem. 1987;48:8\u201315.","journal-title":"J Neurochem"},{"key":"217_CR32","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.neuropsychologia.2004.06.007","volume":"43","author":"M Garcia-Alloza","year":"2005","unstructured":"Garcia-Alloza M, Gil-Bea FJ, Diez-Ariza M, Chen CP, Francis PT, Lasheras B, Ramirez MJ. Cholinergic\u2013serotonergic imbalance contributes to cognitive and behavioral symptoms in Alzheimer\u2019s disease. Neuropsychologia. 2005;43:442\u20139.","journal-title":"Neuropsychologia"},{"key":"217_CR33","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/BF00711237","volume":"12","author":"AJ Nazarali","year":"1992","unstructured":"Nazarali AJ, Reynolds GP. Monoamine neurotransmitters and their metabolites in brain regions in Alzheimer\u2019s disease: a postmortem study. Cell Mol Neurobiol. 1992;12:581\u20137.","journal-title":"Cell Mol Neurobiol"},{"key":"217_CR34","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jns.2009.08.066","volume":"288","author":"SW Tsang","year":"2010","unstructured":"Tsang SW, Keene J, Hope T, Spence I, Francis PT, Wong PT, Chen CP, Lai MK. A serotoninergic basis for hyperphagic eating changes in Alzheimer\u2019s disease. J Neurol Sci. 2010;288:151\u20135.","journal-title":"J Neurol Sci"},{"issue":"8","key":"217_CR35","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.2967\/jnumed.109.063008","volume":"50","author":"Y Ouchi","year":"2009","unstructured":"Ouchi Y, Yoshikawa E, Futatsubashi M, Yagi S, Ueki T, Nakamura K. Altered brain serotonin transporter and associated glucose metabolism in Alzheimer disease. J Nucl Med. 2009;50(8):1260\u20136.","journal-title":"J Nucl Med"},{"issue":"3","key":"217_CR36","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.neurobiolaging.2010.03.023","volume":"33","author":"L Marner","year":"2012","unstructured":"Marner L, Frokjaer VG, Kalbitzer J, Lehel S, Madsen K, Baar\u00e9 WF, Knudsen GM, Hasselbalch SG. Loss of serotonin 2A receptors exceeds loss of serotonergic projections in early Alzheimer\u2019s disease: a combined [11C]DASB and [18F]altanserin-PET study. Neurobiol Aging. 2012;33(3):479\u201387.","journal-title":"Neurobiol Aging"},{"key":"217_CR37","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/00005072-198407000-00001","volume":"43","author":"CA Curcio","year":"1984","unstructured":"Curcio CA, Kemper T. Nucleus raphe dorsalis in dementia of the Alzheimer type: neurofibrillary change and neuronal packing density. J Neuropathol Exp Neurol. 1984;43:359\u201368.","journal-title":"J Neuropathol Exp Neurol"},{"key":"217_CR38","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1007\/BF00227741","volume":"84","author":"GM Halliday","year":"1992","unstructured":"Halliday GM, McCann HL, Pamphlett R, Brooks WS, Creasey H, McCusker E, Cotton RGH, Broe GA, Harper CG. Brain stem serotonin-synthesising neurons in Alzheimer\u2019s disease: a clinicopathological correlation. Acta Neuropathol (Berl). 1992;84:638\u201350.","journal-title":"Acta Neuropathol (Berl)"},{"key":"217_CR39","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/0278-5846(92)90106-O","volume":"16","author":"H Arai","year":"1992","unstructured":"Arai H, Ichimiya Y, Kosaka K, Moroji T, Iizuka R. Neurotransmitter changes in early- and late-onset Alzheimer-type dementia. Prog Neuropsychopharmacol Biol Psychiatry. 1992;16:883\u201390.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"3\u20134","key":"217_CR40","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/jlcr.3011","volume":"56","author":"JS Stehouwer","year":"2013","unstructured":"Stehouwer JS, Goodman MM. (11) C and (18) F PET radioligands for the serotonin transporter (SERT. J Labelled Compd Radiopharm. 2013;56(3\u20134):114\u20139.","journal-title":"J Labelled Compd Radiopharm"},{"issue":"23","key":"217_CR41","doi-asserted-by":"crossref","first-page":"9504","DOI":"10.1073\/pnas.86.23.9504","volume":"86","author":"DM Bowen","year":"1989","unstructured":"Bowen DM, Najlerahim A, Procter AW, Francis PT, Murphy E. Circumscribed changes of the cerebral cortex in neuropsychiatric disorders of later life. Proc Natl Acad Sci USA. 1989;86(23):9504\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"217_CR42","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0006-8993(03)02554-X","volume":"974","author":"MK Lai","year":"2003","unstructured":"Lai MK, Tsang SW, Francis PT, Esiri MM, Keene J, Hope T, Chen CP. Reduced serotonin 5-HT1A receptor binding in the temporal cortex correlates with aggressive behavior in Alzheimer disease. Brain Res. 2003;974:82\u20137.","journal-title":"Brain Res"},{"key":"217_CR43","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1073\/pnas.0510237103","volume":"103","author":"V Kepe","year":"2006","unstructured":"Kepe V, Barrio JR, Huang SC, Ercoli L, Siddarth P, Shoghi-Jadid K, Cole GM, Satyamurthy N, Cummings JL, Small GW, Phelps ME. Serotonin 1A receptors in the living brain of Alzheimer\u2019s disease patients. Proc Natl Acad Sci USA. 2006;103:702\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"217_CR44","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/sj.npp.1300330","volume":"29","author":"M Garcia-Alloza","year":"2004","unstructured":"Garcia-Alloza M, Hirst WD, Chen CP, Lasheras B, Francis PT, Ramirez MJ. Differential involvement of 5-HT(1B\/1D) and 5-HT6 receptors in cognitive and non-cognitive symptoms in Alzheimer\u2019s disease. Neuropsychopharmacology. 2004;29:410\u20136.","journal-title":"Neuropsychopharmacology"},{"key":"217_CR45","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/0006-8993(87)91408-9","volume":"401","author":"AM Palmer","year":"1987","unstructured":"Palmer AM, Wilcock GK, Esiri MM, Francis PT, Bowen DM. Monoaminergic innervation of the frontal and temporal lobes in Alzheimer\u2019s disease. Brain Res. 1987;401:231\u20138.","journal-title":"Brain Res"},{"issue":"1","key":"217_CR46","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1136\/jnnp.56.1.80","volume":"56","author":"PT Francis","year":"1993","unstructured":"Francis PT, Pangalos MN, Stephens PH, Bartlett JR, Bridges PK, Malizia AL, Neary D, Procter AW, Thomas DJ, Bowen DM. Antemortem measurements of neurotransmission: possible implications for pharmacotherapy of Alzheimer\u2019s disease and depression. J Neurol Neurosurg Psychiatry. 1993;56(1):80\u20134.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"217_CR47","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1111\/j.1476-5381.1995.tb15020.x","volume":"115","author":"SN Dijk","year":"1995","unstructured":"Dijk SN, Francis PT, Stratmann GC, Bowen DM. NMDA-induced glutamate and aspartate release from rat cortical pyramidal neurones: evidence for modulation by a 5-HT 1A antagonist. Br J Pharmacol. 1995;115:1169\u201374.","journal-title":"Br J Pharmacol"},{"key":"217_CR48","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1124\/jpet.105.086363","volume":"314","author":"LE Schechter","year":"2005","unstructured":"Schechter LE, Smith DL, Rosenzweig-Lipson S, Sukoff SJ, Dawson LA, Marquis K, Jones D, Piesla M, Andree T, Nawoschik S, Harder JA, Womack MD, Buccafusco J, Terry AV, Hoebel B, Rada P, Kelly M, Abou-Gharbia M, Barrett JE, Childers W. Lecozotan (SRA-333): a selective serotonin 1A receptor antagonist that enhances the stimulated release of glutamate and acetylcholine in the hippocampus and possesses cognitive-enhancing properties. J Pharmacol Exp Ther. 2005;314:1274\u201389.","journal-title":"J Pharmacol Exp Ther"},{"key":"217_CR49","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/sj.clpt.6100232","volume":"83","author":"S Raje","year":"2008","unstructured":"Raje S, Patat AA, Parks V, Schechter L, Plotka A, Paul J, Langstrom B. A positron emission tomography study to assess binding of lecozotan, a novel 5-hydroxytryptamine-1A silent antagonist, to brain 5-HT1A receptors in healthy young and elderly subjects, and in patients with Alzheimer\u2019s disease. Clin Pharmacol Ther. 2008;83:86\u201396.","journal-title":"Clin Pharmacol Ther"},{"key":"217_CR50","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.pbb.2010.02.008","volume":"95","author":"M Skirzewski","year":"2010","unstructured":"Skirzewski M, Hernandez L, Schechter LE, Rada P. Acute lecozotan administration increases learning and memory in rats without affecting anxiety or behavioral depression. Pharmacol Biochem Behav. 2010;95:325\u201330.","journal-title":"Pharmacol Biochem Behav"},{"key":"217_CR51","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1365-2125.2008.03348.x","volume":"67","author":"A Patat","year":"2009","unstructured":"Patat A, Parks V, Raje S, Plotka A, Chassard D, Le Coz F. Safety, tolerability, pharmacokinetics and pharmacodynamics of ascending single and multiple doses of lecozotan in healthy young and elderly subjects. Br J Clin Pharmacol. 2009;67:299\u2013308.","journal-title":"Br J Clin Pharmacol"},{"key":"217_CR52","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.amjopharm.2009.06.003","volume":"7","author":"MN Sabbagh","year":"2009","unstructured":"Sabbagh MN. Drug development for Alzheimer\u2019s disease: where are we now and where are we headed? Am J Geriatr Pharmacother. 2009;7:167\u201385.","journal-title":"Am J Geriatr Pharmacother"},{"key":"217_CR53","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s00213-010-1936-2","volume":"213","author":"MK Lai","year":"2011","unstructured":"Lai MK, Tsang SW, Esiri MM, Francis PT, Wong PT, Chen CP. Differential involvement of hippocampal serotonin 1A receptors and re-uptake sites in non-cognitive behaviors of Alzheimer\u2019s disease. Psychopharmacology. 2011;213:431\u20139.","journal-title":"Psychopharmacology"},{"key":"217_CR54","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1017\/S1461145706007000","volume":"10","author":"S Sato","year":"2007","unstructured":"Sato S, Mizukami K, Asada T. A preliminary open-label study of 5-HT1A partial agonist tandospirone for behavioural and psychological symptoms associated with dementia. Int J Neuropsychopharmacol. 2007;10:281\u20133.","journal-title":"Int J Neuropsychopharmacol"},{"key":"217_CR55","doi-asserted-by":"crossref","first-page":"25s","DOI":"10.1016\/S0924-9338(00)00525-3","volume":"Suppl 1","author":"C Salzman","year":"2001","unstructured":"Salzman C. Treatment of the agitation of late-life psychosis and Alzheimer\u2019s disease. Eur Psychiatry. 2001;Suppl 1:25s\u20138s.","journal-title":"Eur Psychiatry."},{"key":"217_CR56","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.neuropharm.2011.02.026","volume":"61","author":"F Shen","year":"2011","unstructured":"Shen F, Smith JA, Chang R, Bourdet DL, Tsuruda PR, Obedencio GP, Beattie DT. 5-HT(4) receptor agonist mediated enhancement of cognitive function in vivo and amyloid precursor protein processing in vitro: a pharmacodynamic and pharmacokinetic assessment. Neuropharmacology. 2011;61:69\u201379.","journal-title":"Neuropharmacology"},{"issue":"9","key":"217_CR57","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1002\/jps.23542","volume":"102","author":"A Sawant-Basak","year":"2013","unstructured":"Sawant-Basak A, Coffman KJ, Walker GS, Ryder TF, Tseng E, Miller E, Lee C, Vanase-Frawley MA, Wong JW, Brodney MA, Rapp T, Obach RS. Metabolism of a serotonin-4 receptor partial agonist 4-{4-[4-tetrahydrofuran-3-yloxy)-benzo[d]isoxazol-3-yloxymethyl]-piperidin-1-ylmethyl}-tetrahydropyran-4-ol (TBPT): identification of an unusual pharmacologically active cyclized oxazolidine metabolite in human. J Pharm Sci. 2013;102(9):3277\u201393.","journal-title":"J Pharm Sci"},{"key":"217_CR58","doi-asserted-by":"crossref","first-page":"S538","DOI":"10.1016\/j.jalz.2010.05.1937","volume":"6","author":"A Fujiuchi","year":"2010","unstructured":"Fujiuchi A, Sugiura A, Ohshiro H, Watanabe S, Yamamoto T, Take Y. RQ-00000009, a selective 5-HT4 receptor partial agonist, suppressed brain amyloid-\u03b2 protein levels and improved memory and cognitive performances in rodents. Alzheimer\u2019s Dementia. 2010;6:S538.","journal-title":"Alzheimer\u2019s Dementia"},{"key":"217_CR59","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1111\/j.1460-9568.2006.05003.x","volume":"24","author":"B Marcos","year":"2006","unstructured":"Marcos B, Gil-Bea FJ, Hirst WD, Garc\u00eda-Alloza M, Ram\u00edrez MJ. Lack of localization of 5-HT6 receptors on cholinergic neurons: implication of multiple neurotransmitter systems in 5-HT6 receptor-mediated acetylcholine release. Eur J Neurosci. 2006;24:1299\u2013306.","journal-title":"Eur J Neurosci"},{"key":"217_CR60","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1517\/13543776.2010.494661","volume":"20","author":"AV Ivachtchenko","year":"2010","unstructured":"Ivachtchenko AV, Ivanenkov YA, Tkachenko SE. 5-hydroxytryptamine subtype 6 receptor modulators: a patent survey. Expert Opin Ther. 2010;20:1171\u201396.","journal-title":"Expert Opin Ther"},{"key":"217_CR61","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0079-6468(09)04805-X","volume":"48","author":"D Witty","year":"2009","unstructured":"Witty D, Ahmed M, Chuang TT. Advances in the design of 5-HT6 receptor ligands with therapeutic potential. Prog Med Chem. 2009;48:163\u2013224.","journal-title":"Prog Med Chem"},{"key":"217_CR62","doi-asserted-by":"crossref","first-page":"79P","DOI":"10.2967\/jnumed.107.044149","volume":"49","author":"L Martarello","year":"2008","unstructured":"Martarello L, Parker C, Cunningham V, Searle G, Rabiner E, Gee A, Davy M, Laruelle M. First evaluation in humans of [11C]GSK215083 as a probe to image the 5-HT6 receptors. J Nucl Med. 2008;49:79P.","journal-title":"J Nucl Med"},{"key":"217_CR63","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/B978-0-12-385902-0.00002-4","volume":"96","author":"A Meneses","year":"2011","unstructured":"Meneses A, P\u00e9rez-Garc\u00eda G, Ponce-Lopez T, Castillo C. 5-HT6 receptor memory and amnesia: behavioral pharmacology\u2014learning and memory processes. Int Rev Neurobiol. 2011;96:27\u201347.","journal-title":"Int Rev Neurobiol"},{"key":"217_CR64","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ejphar.2006.09.049","volume":"553","author":"WD Hirst","year":"2006","unstructured":"Hirst WD, Stean TO, Rogers DC, Sunter D, Pugh P, Moss SF, Bromidge SM, Riley G, Smith DR, Bartlett S, Heidbreder CA, Atkins AR, Lacroix LP, Dawson LA, Foley AG, Regan CM, Upton N. SB-399885 is a potent, selective 5-HT6 receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition models. Eur J Pharmacol. 2006;553:109\u201319.","journal-title":"Eur J Pharmacol"},{"key":"217_CR65","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00213-011-2627-3","volume":"2221","author":"V Da Silva Costa-Aze","year":"2012","unstructured":"Da Silva Costa-Aze V, Dauphin F, Boulouard M. 5-HT6 receptor blockade differentially affects scopolamine-induced deficits of working memory, recognition memory and aversive learning in mice. Psychopharmacology. 2012;2221:99\u2013115.","journal-title":"Psychopharmacology"},{"key":"217_CR66","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.nlm.2011.06.015","volume":"96","author":"NM Bruin de","year":"2011","unstructured":"de Bruin NM, Prickaerts J, van Loevezijn A, Venhorst J, de Groote L, Houba P, Reneerkens O, Akkerman S, Kruse CG. Two novel 5-HT6 receptor antagonists ameliorate scopolamine-induced memory deficits in the object recognition and object location tasks in Wistar rats. Neurobiol Learn Mem. 2011;96:392\u2013402.","journal-title":"Neurobiol Learn Mem"},{"issue":"5","key":"217_CR67","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1002\/gps.2562","volume":"26","author":"G Maher-Edwards","year":"2011","unstructured":"Maher-Edwards G, Dixon R, Hunter J, Gold M, Hopton G, Jacobs G, Hunter J, Williams P. SB-742457 and donepezil in Alzheimer disease: a randomized, placebo-controlled study. Int J Geriatr Psychiatry. 2011;26(5):536\u201344.","journal-title":"Int J Geriatr Psychiatry"},{"key":"217_CR68","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/alzrt49","volume":"2","author":"RW Jones","year":"2010","unstructured":"Jones RW. Dimebon disappointment. Alzheimer\u2019s Res Ther. 2010;2:25.","journal-title":"Alzheimer\u2019s Res Ther"},{"key":"217_CR69","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0140-6736(08)61074-0","volume":"372","author":"RS Doody","year":"2008","unstructured":"Doody RS, Gavrilova SI, Sano M, Thomas RG, Aisen PS, Bachurin SO, Seely L, Hung D, Dimebon Investigators. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer\u2019s disease: a randomised, double-blind, placebo controlled study. Lancet. 2008;372:207\u201315.","journal-title":"Lancet"},{"issue":"5","key":"217_CR70","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1021\/ja108211m","volume":"133","author":"KS MacMillan","year":"2011","unstructured":"MacMillan KS, Naidoo J, Liang J, Melito L, Williams NS, Morlock L, Huntington PJ, Estill SJ, Longgood J, Becker GL, McKnight SL, Pieper AA, De Brabander JK, Ready JM. Development of proneurogenic, neuroprotective small molecules. J Am Chem Soc. 2011;133(5):1428\u201337.","journal-title":"J Am Chem Soc"},{"issue":"2","key":"217_CR71","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/j.1476-5381.2012.02022.x","volume":"167","author":"S Woods","year":"2012","unstructured":"Woods S, Clarke NN, Layfield R, Fone KC. 5-HT(6) receptor agonists and antagonists enhance learning and memory in a conditioned emotion response paradigm by modulation of cholinergic and glutamatergic mechanisms. Br. J. Pharmacol. 2012;167(2):436\u201349.","journal-title":"Br. J. Pharmacol"},{"key":"217_CR72","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s00213-010-1854-3","volume":"213","author":"I Kendall","year":"2011","unstructured":"Kendall I, Slotten HA, Codony X, Burgue\u00f1o J, Pauwels PJ, Vela JM, Fone KC. E-6801, a 5-HT6 receptor agonist, improves recognition memory by combined modulation of cholinergic and glutamatergic neurotransmission in the rat. Psychopharmacology. 2011;213:413\u201330.","journal-title":"Psychopharmacology"},{"key":"217_CR73","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/jcp.0b013e31814b98c1","volume":"27","author":"A Mowla","year":"2007","unstructured":"Mowla A, Mosavinasab M, Haghshenas H, Borhani Haghighi A. Does serotonin augmentation have any effect on cognition and activities of daily living in Alzheimer\u2019s dementia? A double-blind, placebo-controlled clinical trial. J Clin Psychopharmacol. 2007;27:484\u20137.","journal-title":"J Clin Psychopharmacol"},{"key":"217_CR74","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/JCP.0b013e31802e0002","volume":"27","author":"A Mowla","year":"2007","unstructured":"Mowla A, Mosavinasab M, Pani A. Does fluoxetine have any effect on the cognition of patients with mild cognitive impairment? A double-blind, placebo-controlled, clinical trial. J Clin Psychopharmacol. 2007;27:67\u201370.","journal-title":"J Clin Psychopharmacol"},{"key":"217_CR75","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/gps.998","volume":"19","author":"SI Finkel","year":"2004","unstructured":"Finkel SI, Mintzer JE, Dysken M, Krishnan KR, Burt T, McRae T. A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer\u2019s disease in outpatients treated with donepezil. Int J Geriatr Psychiatry. 2004;19:9\u201318.","journal-title":"Int J Geriatr Psychiatry"},{"key":"217_CR76","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jalz.2011.01.007","volume":"8","author":"LT Drye","year":"2012","unstructured":"Drye LT, Ismail Z, Porsteinsson AP, Rosenberg PB, Weintraub D, Marano C, Pelton G, Frangakis C, Rabins PV, Munro CA, Meinert CL, Devanand DP, Yesavage J, Mintzer JE, Schneider LS, Pollock BG, Lyketsos CG, CitAD Research Group. Citalopram for agitation in Alzheimer\u2019s disease: design and methods. Alzheimers Dement. 2012;8:121\u201330.","journal-title":"Alzheimers Dement"},{"key":"217_CR77","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1097\/JGP.0b013e31826ce4c5","volume":"20","author":"CA Munro","year":"2012","unstructured":"Munro CA, Longmire CF, Drye LT, Martin BK, Frangakis CE, Meinert CL, Mintzer JE, Porsteinsson AP, Rabins PV, Rosenberg PB, Schneider LS, Weintraub D, Lyketsos CG, Depression in Alzheimer\u2019s Disease Study-2 Research Group. Cognitive outcomes after sertraline treatment in patients with depression of Alzheimer disease. Am J Geriatr Psychiatry. 2012;20:1036\u201344.","journal-title":"Am J Geriatr Psychiatry"},{"key":"217_CR78","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1097\/JGP.0b013e3181c796eb","volume":"18","author":"PB Rosenberg","year":"2010","unstructured":"Rosenberg PB, Drye LT, Martin BK, Frangakis C, Mintzer JE, Weintraub D, Porsteinsson AP, Schneider LS, Rabins PV, Munro CA, Meinert CL, Lyketsos CG; DIADS-2 Research Group. Sertraline for the treatment of depression in Alzheimer disease. Am J Geriatr Psychiatry. 2010;18:136\u201345.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"36","key":"217_CR79","doi-asserted-by":"crossref","first-page":"14968","DOI":"10.1073\/pnas.1107411108","volume":"108","author":"JR Cirrito","year":"2011","unstructured":"Cirrito JR, Disabato BM, Restivo JL, Verges DK, Goebel WD, Sathyan A, Hayreh D, D\u2019Angelo G, Benzinger T, Yoon H, Kim J, Morris JC, Mintun MA, Sheline YI. Serotonin signaling is associated with lower amyloid-\u03b2 levels and plaques in transgenic mice and humans. Proc Natl Acad Sci USA. 2011;108(36):14968\u201373.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"217_CR80","doi-asserted-by":"crossref","first-page":"420","DOI":"10.2174\/1567205011310040007","volume":"10","author":"E Martisova","year":"2013","unstructured":"Martisova E, Aisa B, Guere\u00f1u G, Ram\u00edrez MJ. Effects of early maternal separation on biobehavioral and neuropathological markers of Alzheimer\u2019s disease in adult male rats. Curr Alzheimer Res. 2013;10(4):420\u201332.","journal-title":"Curr Alzheimer Res"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-014-0217-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-014-0217-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-014-0217-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T04:47:28Z","timestamp":1648961248000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-014-0217-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":80,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["217"],"URL":"https:\/\/doi.org\/10.1007\/s40265-014-0217-5","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5]]}}}